Hematologic Oncology | Specialty

The hematologic oncology condition center is a comprehensive resource for clinical news and expert insights on hematologic oncology. Read more at OncLive.

Dr Garfall on the Potential Role for Consolidation or Maintenance CAR T-Cell Therapy in Myeloma

March 5th 2025

Alfred Garfall, MD, discusses the potential role of CAR T-cell therapy in multiple myeloma either as consolidation or maintenance in the up-front setting.

Dr Podoltsev on Blinatumomab Plus Consolidation Chemotherapy in Older BCR-ABL1–Negative ALL

March 4th 2025

Nikolai Podoltsev, MD, PhD, discusses the addition of blinatumomab to consolidation chemotherapy in older patients with newly diagnosed BCR-ABL1–negative ALL.

Ivosidenib/CPX-351 Shows Early Activity and Is Safe in IDH1-Mutated R/R AML, High-Risk MDS

March 4th 2025

Treatment with ivosidenib plus CPX-351 showed early efficacy in patients with relapsed/refractory AML or high-risk MDS harboring an IDH1 mutation.

FDA Grants Orphan Drug Designation to Bexmarilimab for Myelodysplastic Syndromes

March 4th 2025

The FDA has granted orphan drug designation to bexmarilimab for myelodysplastic syndromes.

Five Under 5: Top Oncology Videos for the Week of 2/23

March 2nd 2025

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

The OncFive: Top Oncology Articles for the Week of 2/23

March 1st 2025

Perioperative pembrolizumab sBLA gets priority review in HNSCC, nivolumab/ipilimumab sBLA in MSI-H/dMMR CRC is under review, and more from OncLive this week.

OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025

March 1st 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Dr Shah on the Rationale for Evaluating Zamto-Cel in R/R DLBCL

March 1st 2025

Nirav N. Shah, MD, discusses how zamto-cel might address resistance to prior CD19-directed therapy in patients with relapsed/refractory DLBCL.

CHMP Recommends Approval of Glofitamab Plus Chemotherapy for R/R DLBCL

February 28th 2025

CHMP has recommended glofitamab plus gemcitabine and oxaliplatin for R/R DLBCL.

Pirtobrutinib Earns Positive CHMP Opinion for R/R CLL After a Covalent BTK Inhibitor

February 28th 2025

The CHMP has recommended the European approval of pirtobrutinib for relapsed/refractory CLL previously treated with a covalent BTK inhibitor.

Targeting Menin: A New Frontier in Treating Refractory Leukemias

February 28th 2025

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Dr Kitko on Clinical Outcomes With Axatilimab According to Prior Lines of Therapy for Chronic GVHD

February 27th 2025

Carrie L. Kitko, MD, discusses outcomes with axatilimab in patients with chronic graft-vs-host-disease according to prior lines of therapy received.

Dr Riedell on the Rationale for Evaluating Rapcabtagene Autoleucel in R/R DLBCL

February 27th 2025

Peter Riedell, MD, highlights the rationale for investigating CAR T-cell therapy rapcabtagene autoleucel in relapsed/refractory DLBCL.

Escalating Lymphodepletion ± Rituximab Before CD19-Directed CAR T-Cell Therapy is Safe in R/R DLBCL

February 27th 2025

Escalating doses of lymphodepleting chemotherapy with or without rituximab prior to CAR T-cell therapy was safe in relapsed/refractory DLBCL.

FDA Accepts Resubmission of BLA for Odronextamab in R/R Follicular Lymphoma

February 26th 2025

The resubmission of a BLA for odronextamab was accepted by the FDA for the treatment of patients with relapsed/refractory follicular lymphoma.

AUTX-703 Receives FDA Fast Track Designation in Relapsed/Refractory AML

February 24th 2025

The FDA has granted the novel, oral KAT2A/B degrader AUTX-703 fast track designation for the treatment of patients with relapsed/refractory AML.

Five Under 5: Top Oncology Videos for the Week of 2/16

February 23rd 2025

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Odronextamab Shows Efficacy, Safety in R/R DLBCL After Progression Post–CAR T-Cell Therapy

February 21st 2025

Odronextamab produced durable responses in relapsed/refractory diffuse large B-cell lymphoma after disease progression following CAR T-cell therapy.

Dr Falchi on Long-Term Outcomes of Fixed-Duration Epcoritamab Plus R-CHOP in DLBCL

February 21st 2025

Lorenzo Falchi, MD, discusses the long-term outcomes of fixed-duration epcoritamab plus R-CHOP in previously untreated patients with DLBCL.

Tambiciclib Plus Zanubrutinib Delivers Responses in R/R DLBCL

February 20th 2025

Tambiciclib plus zanubrutinib generated responses in patients with relapsed/refractory diffuse large B-cell lymphoma.